Form 8-K - Current report:
SEC Accession No. 0001159036-25-000047
Filing Date
2025-11-05
Accepted
2025-11-05 16:59:47
Documents
15
Period of Report
2025-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20251105.htm   iXBRL 8-K 39457
2 EX-99.1 ex991halo-launchpressrelea.htm EX-99.1 21809
6 GRAPHIC halo-20251105_g1.jpg GRAPHIC 15840
7 GRAPHIC image_1.jpg GRAPHIC 5251
  Complete submission text file 0001159036-25-000047.txt   221799

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20251105.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20251105_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20251105_pre.xml EX-101.PRE 12522
17 EXTRACTED XBRL INSTANCE DOCUMENT halo-20251105_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 251454919
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)